Mark Leick is an Oncology physician affiliated with Broad Institute. OpenAlex indexes 97 publications with 4,084 citations (h-index 26).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AdaptimmuneProgram year20251 paymentResearch
- BioNTech SEProgram year20251 payment
- BioNTech SEProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor100%Famciclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- Targeted delivery of a VEGF‐blocking scFv by CD70 CAR‐T cells to enhance anti‐tumor activity in renal cell carcinoma
Massachusetts General Hospital
FY2026$297,728K08CA289948 - Targeted delivery of a VEGF‐blocking scFv by CD70 CAR‐T cells to enhance anti‐tumor activity in renal cell carcinoma
Massachusetts General Hospital
FY2025$297,728K08CA289948 - Targeted delivery of a VEGF‐blocking scFv by CD70 CAR‐T cells to enhance anti‐tumor activity in renal cell carcinoma
Massachusetts General Hospital
FY2024$297,728K08CA289948
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Alan Mullen, MD, PhD
Broad Institute
Benjamin Ebert, MD
Broad Institute
Susan Redline, MD
Broad Institute
Patrick Ellinor, MD, PhD
Broad Institute
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”